EGFR and neoplasm: Three cycles of 150 μg of anti-EGFR–IR700 (panitumumab-IR700) followed by the irradiation with NIR-light from two directions (each 20 J/cm2, via the back and the front) significantly reduced tumour growth as measured by serial Magnetic Resonance Imaging (MRI).